mdlinx mdlinx
Dentistry Articles on MDLinx Top Read Articles
of 2012

Efficacy of Subgingivally Delivered Simvastatin in the Treatment of Type 2 Diabetes Subjects With Chronic Periodontitis: A Randomized Double Blinded Controlled Clinical Trial Journal of Periodontology, 03/19/2012

Pradeep AR et al. – There was a greater decrease in modified sulcus bleeding index (mSBI) and probing depth (PD) and more clinical attachment level (CAL) gain with significant intrabony defect (IBD) fill at sites treated with scaling and root planing (SRP) plus locally delivered SMV in type 2 diabetes subjects with chronic periodontitis.

Methods
  • Thirty eight patients were categorized into two treatment groups: SRP plus SMV, 1.2 % and SRP plus placebo.
  • Clinical parameters were recorded at baseline before SRP and at 3, 6 and 9 months; they included modified sulcus bleeding index (mSBI), probing depth (PD), and clinical attachment level (CAL).
  • At baseline, after 6 months and 9 months, radiologic assessment of intrabony defect (IBD) fill was done using computer-aided software.

Results
  • Mean probing depth reduction and mean clinical attachment level gain was found to greater in SMV group than placebo group, at 3, 6 and 9 months.
  • Furthermore, significantly greater mean percentage of bone fill was found in the SMV group (32.64 ± 12.90%) compared to placebo group (4.22 ± 9.75%).

Read this article on Journal of Periodontology



Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close